Bayer Collaborates with CureVac for CVnCoV Against COVID-19

 Bayer Collaborates with CureVac for CVnCoV Against COVID-19

Bayer Collaborates with CureVac for CVnCoV Against COVID-19

Shots:

  • Bayer to support the development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate, CVnCoV and will contribute its expertise and established infrastructure in numerous area
  • Curevac will be the MAH for the product while Bayer will support CureVac with country operations within the EU and additional markets. Additionally, Bayer has an option to MAH outside the EU
  • The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses across the globe

Click here ­to­ read full press release/ article | Ref: Bayer | Image: GMPNews

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post